LATEST UPDATE

Age Reversal Research Update

There has been significant progress on the development of several age-reversal studies. In this message, we share with you an update on three of these studies:

Dasatinib and Quercetin Study

Premise: Senescent cells accumulate with age. These senescent cells:

Impede organ function

Create chronic inflammation

Increase cancer risk with age

Shorten healthy lifespan

No value has been shown from retaining dysfunctional senile cells. Selectively removing senescent cells appears to have profound regenerative effects as demonstrated in several studies, one of which we describe next.

Status of Dasatinib plus Quercetin Human Study

Based on data indicating that senescent cell accumulation underlies several aspects of degenerative aging, a clinical study seeks to identify a safe and effective dosing regimen of dasatinib and quercetin that maturing individuals may consider. Current strategy is to use sporadic doses to prevent or reverse various pathologies. The compounds are being tested using three different dosing schedules, while giving the same total dose to each group. Here is an update on this dasatinib/quercetin study:

Group 1 (receives full dose over 3 weeks) was completed as of August 27, 2017.

Group 2 (receives same total dose as above, but over 2 weeks) will begin on Sept. 1, and end on Sept. 10.

Group 3 will be conducted in Southern California (Thousand Oaks) and the subjects in the study will get the same amount of dasatinib + quercetin as Groups 1 and 2, but via the administration of a single dose. This arm of the study needs to recruit between 10 and 15 people to participate in a four-day process (one day of MRI and blood tests, one day of dosing, and two days of post-treatment blood draws). The dasatinib + quercetin study protocol requires that subjects be at least 65 and no more than 85 years of age, and have metabolic syndrome and/or osteoarthritis. People who don’t meet these criteria are not eligible for this study, as it seeks to demonstrate reversal of these specific degenerative conditions.

For all of these groups, MRIs will be performed at baseline and at about 6 months post-treatment.

This study is pre-funded and there are no costs to study participants.

If you did not yet register for this trial, or want to re-register now, click here.

Rapamycin Study

Premise: As cells age they accumulate metabolic waste that interferes with efficient functionality. Most aging people also suffer from excess mTOR activity, which predisposes them to unwanted fat accumulation along with increased risks of malignancies, atherosclerosis, and dementia. When excess mTOR activity is suppressed, cells start cleansing themselves of toxic waste products via a process called autophagy. Several other regenerative processes become activated as well.The drug rapamycin works to:

Directly turn down mTOR activity

Induce autophagy (rids cells of debris)

Improve bone marrow (immune) function

Decrease cell propagation

Metabolize cellular fat stores

Extend lifespan in animal models

Here is information from a CNN broadcast about the Young Dog Project, where rapamycin appears to be reversing aging in old animals:

There are currently two different rapamycin protocols intended to test for rejuvenation in human elderly. They are being offered in:

Little Neck, New York, with Dr. Alan S. Green, M.D. We are calling this the “Dr. Alan Green Rapamycin Treatment”

Thousand Oaks, California. We are calling this the “Thousand Oaks Rapamycin Study”

Dr. Alan GreenRapamycin Study Case Report

“By 4 months the results were miraculous. I lost 20 pounds, my waist-line went from 38 inches to 33. I bought a pair of size 32 jeans…I could walk 5 miles a day and ride a bike up hills without any hint of angina…Creatinine went from elevated to normal and fasting blood sugar went down. I thought I was Lazarus back from the dead. It’s now over 1 year and I feel great.

Status of the Thousand Oaks Rapamycin Study

A year-long clinical trial using once-a-week doses of rapamycin aims to begin in early October, 2017, in Thousand Oaks, California. This pre-funded study seeks to recruit at least 30 people ages 60-85 years who fit the eligibility criteria. We recently sent an email inviting individuals serious about being participants to contact the study coordinator, expressing their interest in participating in this study.

There is no cost to participate in this study, which seeks to identify the effects of once-per-week dosing of rapamycin on a wide range of clinical measures and aging biomarkers.

To clarify, there are two options if you wish to initiate rapamycin once-weekly dosing as follows:

Become a patient of Dr. Alan Green or have your doctor consider following Dr. Green’s rapamycin treatment protocol that is open-sourced at:

Enroll as a potential subject in the Thousand Oaks Rapamycin Studyby clicking here. If you already registered your interested in this study, then you should have received an email about enrollment.

NAD+ Infusion Study

Premise: A cellular coenzyme called NAD+is essential for numerous life sustaining processes, but declines markedly with age. By age 50, a person may have only half the NAD+ they had in youth. By age 80, only 1 to 10 percent of NAD+ levels expressed in youth may be present. Deficiency of NAD+ appears to predispose people to accelerated aging. Below are some benefits of NAD+ and suggestions for your consideration:

Several arms of the NAD+ studies, including intravenous infusions, intramuscular injections, and iontophoresis patches, have been completed and there are now clinics around the country offering NAD+ infusions for potential reversal of age-related disorders.

Some of these clinics offer in-home infusions at a higher cost, but you can travel to the clinics for daily infusions that usually cost less money. Infusions cost about $1,000 to $1,500 per day.

Scientists are currently evaluating differing doses for each NAD+ infusion and will convey their suggestions to doctors who have registered on the www.RescueElders.org website.

We expect there will soon be doctors in most metropolitan areas prescribing NAD+ infusions. We are working with physicians in Europe and elsewhere to help develop clinics offering NAD+ infusions around the world. Here is a list of doctors in the U.S. who may prescribe NAD+ infusions for its potential age reversal effects today: